School of Medicine
Showing 101-200 of 613 Results
-
Mardi Karin, MD, FACS
Clinical Associate Professor, Surgery - General Surgery
Bio Dr. Mardi R. Karin is a board certified surgeon with over 20 years of experience and the clinical director of breast cancer care at Stanford Cancer Center South Bay. Dr. Karin specializes in the diagnosis and treatment of breast diseases and cancer. Her focus and leadership in breast cancer care includes improving coordinated care for breast cancer treatment, developing optimal survivorship plans, and extensive experience in building strong relationships with community physicians. Dr. Karin has extensive experience in a wide variety of general surgery procedures and all types of breast surgery, including breast conservation treatment. In addition, Dr. Karin is well experienced in complex breast cancer skin and nipple sparing procedures in coordination with the plastic surgeon for immediate breast reconstruction and optimal appearance with excellent outcomes.
-
Michele Kastelein
Clinical Assistant Professor, Medicine - Vaden Health Center
Current Research and Scholarly Interests At Stanford University School of Medicine, one of our major goals is to translate research insights into practical advances that enhance and prolong life. We foster a two-way transfer of knowledge between research laboratories and patient-care settings. Our faculty, staff, postdoctoral scholars and students engage in interdisciplinary efforts to turn this knowledge into therapies that treat or prevent disease.
-
Max Kasun
Bio Max Kasun works in the Roberts Ethics Lab at Stanford.
-
Tamiko Katsumoto
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
Bio Tamiko Katsumoto, MD, is a Clinical Assistant Professor in the Division of Immunology and Rheumatology at Stanford University. She earned her MD from the University of California, San Francisco. She completed her internal medicine residency and rheumatology fellowship at UCSF, including a postdoc in the immunology lab of Dr. Arthur Weiss. Dr. Katsumoto’s research interests include the discovery of novel biomarkers to predict the development of immune-related adverse events in cancer patients on immune checkpoint inhibitor therapies, and optimizing the management of such complications. She is fascinated by the relationship between cancer and autoimmune diseases such as scleroderma and dermatomyositis, the paraneoplastic manifestations of various cancers, and the rheumatic complications of graft vs. host disease. She has spent time at Genentech, where she led several clinical trials in immunology. She also serves as a grant reviewer for the American College of Rheumatology Translational/Clinical Study Section and serves on the Medical and Scientific Board of the Northern California Chapter of the Arthritis Foundation.
-
David Katzenstein
Professor (Research) of Medicine (Infectious Diseases and Geographic Medicine), Emeritus
Current Research and Scholarly Interests Treatment and evaluation of HIV infectionin the United States and Europe through the AIDS Clinical Trials Group (ACTG). International HIV pathogenesis work includes studies in Zimbabwe, South Africa, and India where we are particularly interested in the pandemic of subtype C HIV-1, TB and other co-infections. The lab currently is focused on drug resistance, envelope tropism and the pathogenesis of HIV.
-
Laurence Katznelson, MD
Professor of Neurosurgery and of Medicine (Endocrinology) at the Stanford University Medical Center, Lucile Salter Packard Children's Hospital and at the Palo Alto Veterans Affairs Health Care System
Current Research and Scholarly Interests Dr. Katznelson is an internationally known neuroendocrinologist and clinical researcher, with research expertise in the diagnosis and management of hypopituitarism, the effects of hormones on neurocognitive function, and the development of therapeutics for acromegaly and Cushings syndrome, and neuroendocrine tumors. Dr. Katznelson is the medical director of the multidisciplinary Stanford Pituitary Center, a program geared for patient management, clinical research and patient education
-
Makoto Kawai
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Stanford Center for Sleep Sciences and Medicine
Bio I am a physician scientist in the field of sleep medicine in aging and brain function. Using combined polysomnogram and novel neuroimaging technology, I aim to identify potential sleep biomarkers to investigate the mechanism of progression from normal aging to Mild Cognitive Impairment (MCI) or dementia. I also investigate the impact of sleep on cognitive/affective function or behavior abnormality in various neurodevelopmental and neurodegenerative disorders.
-
Masataka Kawana
Instructor, Medicine - Cardiovascular Medicine
Bio Dr. Kawana joined Advanced Heart Failure and Transplant Cardiology group in 2018 as an Instructor in the Division of Cardiovascular Medicine. He completed his internal medicine, cardiovascular medicine and heart failure training at Stanford. He also completed postdoctoral research fellowship under Dr. James Spudich in Department of Biochemistry. He sees advanced heart failure patients in clinic, and attends on inpatient service taking care of post-heart transplant patients and patients on MCS support. His research interests are in the fundamental mechanism of inherited cardiomyopathies, and he studies the effect of gene mutation on the cardiac sarcomere function using cutting-edge biochemical and biophysical approach, which would lead to development of novel pharmacotherapy that directly modulates cardiac muscle protein.
-
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor in Pediatrics, and Professor of Genetics
Current Research and Scholarly Interests Mark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
-
Debra Lee Kaysen
Professor of Psychiatry and Behavioral Sciences (Public Mental Health & Population Sciences) at the Stanford University Medical Center
Bio Debra Kaysen received her PhD in Clinical Psychology from the University of Missouri. She completed an internship at the University of Washington and continued there to complete an NIAAA-funded F32 to study the area of overlap between PTSD and alcohol use disorders. Dr. Kaysen joined the faculty at University of Washington in 2006 in the Department of Psychiatry and Behavioral Sciences. While there she founded a program to develop and test more accessible interventions for individuals suffering from mental health symptoms following traumatic events. Dr. Kaysen joined the Stanford faculty in 2019.
Dr. Kaysen’s area of specialty both in research and clinical work is in treatment of those who have experienced traumatic events including PTSD, mood and substance use disorders. She has conducted critical studies on bidirectional relationships between PTSD and alcohol use, and on the treatment of PTSD and/or substance use across a variety of populations (sexual minority women, Native Americans, young adult sexual assault survivors, active duty military) and in a variety of settings (the Democratic Republic of Congo, Iraq, primary care, rural settings). Dr. Kaysen has been on the Board of Directors for the International Society for Traumatic Stress Studies (ISTSS) since 2013 and is currently the ISTSS President-Elect. Her research has been funded by the National Institute of Alcohol Abuse and Alcoholism, the National Institute of Drug Abuse, the National Institute on Minority Health and Health Disparities, the Department of Defense, and USAID. -
Electron Kebebew, MD, FACS
Harry A. Oberhelman, Jr. and Mark L. Welton Professor
Current Research and Scholarly Interests Dr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.
-
Corey Keller, MD, PhD
Instructor, Psychiatry and Behavioral Sciences
Current Research and Scholarly Interests The overarching goal of my research is to identify and apply individualized stimulation protocols to elicit precise and predictable long-term plasticity in order to alleviate psychiatric suffering. Repetitive transcranial magnetic stimulation (TMS) was FDA approved for treatment-resistant depression over 10 years ago as a circuit-based, targeted intervention that complements traditional psychiatric treatments. Remission rates, however, remain at 15% at worst and 40% at best. TMS trials using identical treatment settings are currently underway for bipolar disorder, PTSD, OCD, and addiction. The low efficacy and one-size-fits-all treatment (with respect to timing, site, and intensity) stems from our lack of understanding of how TMS induces brain changes. It is reasonable to expect that we can improve the efficacy of TMS. By selecting the optimal parameters based on the stimulation timing, location, intensity, and duration of the TMS pulses, we can customize treatment to maximize an individual’s clinical response. My 10 year research aims are to obtain this level of specificity and treatment response by:
1) Developing an integrated translational clinical research program.
2) Identifying the specific neural mechanisms underlying repetitive stimulation-induced plasticity.
3) Creating novel treatments with TMS based on experimentally-driven computational models of plasticity.
This three-pronged approach has the expected outcome of producing novel stimulation treatments with enhanced specificity, plasticity, and efficacy. By increasing our understanding of the underlying mechanism and monitoring of brain changes during TMS, we will markedly increase the utility of these powerful techniques. Together, this work will help transform interventional psychiatry from an isolated (from a clinic perspective), one-size-fits-all treatment approach to one that focuses on targeting objective biomarkers and that is collaborative, large-scale, and automated, pushing the field into the age of personalized neuromodulation. -
Jennifer Keller
Clinical Associate Professor, Psychiatry and Behavioral Sciences
Current Research and Scholarly Interests interpersonal violence and abuse prevention; empowerment of women; cognitive and affective information processing in depression; clinical, biological, and neuropsychological aspects of depression; South Asian mental health
-
Richard Kempson
Professor of Pathology, Emeritus
Current Research and Scholarly Interests Clinicopathologic studies in endometrial carcinoma, ovarian neoplasms, and soft tissue tumors.
-
Joan Kendig
Professor of Biology in the Department of Anesthesia, Emeritus
Current Research and Scholarly Interests My laboratory tries to find out how pharmacologic agents used in the practice of anesthesia (general anesthetic and analgesic agents) lead to therapeutically desireable endpoints including unconsciousness, immobility and absence of pain. The old idea that general anesthetics are uniformly non-specific "membrane stabilizers" is giving way to a new realization that these agents exert specific actions on particular ion channels and intracellular signalling systems.
-
Matthew Kendra
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Current Research and Scholarly Interests Stigma, help-seeking, access to mental health services, and substance use
